Alcoholic Hepatitis Treatment Market By Treatment Type (Supportive Care & Nutritional Therapy, Corticosteroid Therapy, Adjunctive Pharmacological Therapy, Alcohol Use Disorder Treatment, Liver Transplantation, Emerging Therapies); By Drug Class (Corticosteroids, N-Acetylcysteine, Alcohol Use Disorder Drugs, Investigational Disease-Modifying Drugs, Other Supportive Medicines); By Disease Severity (Mild Alcoholic Hepatitis, Moderate Alcoholic Hepatitis, Severe Alcoholic Hepatitis); By Route of Administration (Oral, Intravenous/Parenteral); By End User (Hospitals, Transplant Centers, Hepatology Clinics, Outpatient Addiction Care Centers, Research Institutes & Clinical Trial Sponsors); By Region, Segment Revenue Estimation, Forecast, 2026–2032

Alcoholic Hepatitis Treatment Market: High Inpatient Costs, Steroid Nonresponse, and Phase 3 Drug Development Reshape Commercial Opportunity

The Global Alcoholic Hepatitis Treatment Market is projected to expand from USD 2.85 billion in 2025 to USD 4.07 billion by 2032, growing at a CAGR of 5.23%, driven by the rising liver disease burden, alcohol-related liver damage, hepatology therapeutics, corticosteroid therapy, biologic treatments, and clinical research, according to Strategic Market Research.

 

The alcoholic hepatitis treatment market remains limited by the lack of approved disease-specific medicines. Alcohol-associated hepatitis can lead to acute liver failure and carries high short-term mortality, yet neither the U.S. FDA nor the EMA has approved a dedicated therapy. Current management relies on alcohol abstinence, nutritional support, generic corticosteroids, treatment of infections and organ failure, and liver transplantation for selected patients.

 

Commercial activity extends beyond prednisolone to hospital medicines, nutritional support, laboratory monitoring, intensive care, renal therapy, alcohol-use-disorder treatment, transplantation, and investigational drugs. The clearest pharmaceutical need remains in severe cases where corticosteroids are unsuitable, ineffective, or fail to improve short-term survival.

 

Severe Hospitalized Patients Represent the Main Pharmaceutical Opportunity

Mortality varies significantly by disease severity. Alcohol-associated hepatitis does not carry a uniform 30-day mortality rate of 50% across all patients. Clinical literature places 30-day mortality at approximately 30% to 50% among severe cases. The National Institute on Alcohol Abuse and Alcoholism reports three-month mortality of 20% to 40% in severe disease, rising as high as 70% among patients who do not respond to corticosteroids.

Hospital demand is concentrated among patients with severe disease. Mild cases may be managed with abstinence, nutritional support, and monitoring, whereas severe cases often require admission, serial laboratory assessment, infection screening, organ support, and transplant evaluation.

Bausch Health cited approximately 164,000 U.S. hospital admissions involving alcoholic hepatitis in 2021 when announcing its acquisition of DURECT. Although the figure came from a company communication, it indicates the scale of the hospital population being targeted by pharmaceutical developers.

Hospitals and payers will judge new therapies by their effect on 28-day and 90-day survival, transplant-free survival, organ failure, and length of hospital stay.

 

Hospital Costs Strengthen the Case for Effective Medicines

Alcoholic hepatitis creates substantial short-term healthcare expenditure because many patients enter treatment through emergency departments or inpatient admission.

A 2025 U.S. study evaluated 34,974 people diagnosed with alcohol-associated hepatitis across outpatient, emergency, and inpatient settings. During the 30 days after diagnosis, average healthcare costs reached approximately USD 8,345 for outpatient cases, USD 20,990 for emergency department cases, and USD 88,655 for inpatient cases. Compared with the 30 days before diagnosis, expenditure increased by 14%, 266%, and 413%, respectively.

Premium therapies could justify higher pricing if they reduce intensive-care use, infections, kidney failure, readmissions, transplant need, or length of stay. A treatment may still offer clinical and economic value without replacing standard care if it lowers the burden of severe complications.

Hospitals will remain the main treatment setting, with adoption led by hepatologists, transplant centres, critical-care teams, and formulary committees rather than retail pharmacies. New therapies must also act within a narrow treatment window because patients with severe disease may deteriorate rapidly after admission.

 

Corticosteroids Lead Current Drug Use but Deliver Limited Long-Term Benefit

Prednisolone remains the main pharmacological treatment for eligible patients with severe alcoholic hepatitis. A common regimen is 40 mg daily for 28 days. Current guidance identifies corticosteroids as the only established drug class with evidence of short-term survival benefit in selected severe cases.

However, corticosteroids have not demonstrated durable survival improvement. The STOPAH trial found no survival benefit from pentoxifylline. Prednisolone produced a reduction in 28-day mortality that did not reach conventional statistical significance, while no improvement was observed at 90 days or one year.

Corticosteroids account for much of the current treatment volume but generate limited pharmaceutical revenue. Prednisolone is inexpensive, widely available, and offers little scope for product differentiation. Its use is further limited by infection risk, patient eligibility criteria, inconsistent response, and uncertain long-term benefit.

Pentoxifylline has largely lost its treatment role after major trials failed to show survival improvement. Updated American College of Gastroenterology guidance does not recommend it for alcoholic hepatitis. Its decline demonstrates that pipeline products must deliver more than biological activity or improved laboratory measures.

N-acetylcysteine represents a smaller adjunctive segment. A five-day infusion may be combined with corticosteroids in severe disease. Evidence showed improved one-month survival with prednisolone plus N-acetylcysteine compared with prednisolone alone, but the benefit was not sustained at six months.

The present drug market therefore remains dominated by low-cost treatments that offer short-term support without resolving the central need for improved survival beyond the initial hospital period.

 

Steroid Nonresponders Form a Defined High-Need Segment

The Lille score divides severe patients into clinically and commercially distinct groups. Guidelines recommend calculating the score after four or seven days of corticosteroid therapy. A score above 0.45 indicates poor response and supports discontinuation of treatment.

Responders may complete a conventional steroid course, while nonresponders require alternative management, clinical-trial enrollment, transplant evaluation, or palliative care. Patients with severe infections, gastrointestinal bleeding, kidney dysfunction, or other contraindications may be unable to receive corticosteroids from the beginning.

These nonresponder and steroid-ineligible populations are likely to become the first commercial targets for differentiated therapies. Their treatment failure can be documented through existing hospital scoring systems, allowing new drugs to enter a defined treatment position without immediately replacing low-cost corticosteroids across all severe cases.

MELD, Maddrey Discriminant Function, and Lille scoring also support demand for diagnostic and monitoring services by determining severity, treatment eligibility, trial recruitment, and transplant referral.

 

Nutrition and Alcohol Abstinence Expand the Care Market

Malnutrition is common in hospitalized alcoholic hepatitis patients and is associated with worse outcomes. Current guidance recommends approximately 35 kilocalories per kilogram of body weight and 1.2 to 1.5 grams of protein per kilogram each day.

This supports demand for oral supplements, enteral feeding products, vitamin replacement, dietitian services, and hospital nutrition programs. Nutrition remains a supportive segment rather than a disease-modifying treatment, but it generates consistent hospital demand and may continue after discharge.

Long-term survival depends heavily on alcohol abstinence. This broadens the market into addiction medicine, behavioral therapy, rehabilitation, relapse monitoring, and psychiatric care. Acamprosate, naltrexone, and disulfiram are approved in the United States for alcohol use disorder, although disulfiram is generally avoided in liver disease because of potential hepatotoxicity. Baclofen, gabapentin, and topiramate may also be considered in selected patients.

The commercial gap lies in limited integration between hepatology and addiction care. An AASLD review reported that 71% of surveyed gastroenterology and hepatology providers had never prescribed medication for alcohol use disorder, often because of limited training or safety concerns.

Programs that begin addiction treatment during hospitalization may improve both long-term outcomes and the economic value of acute care. Without sustained abstinence, expensive hospital treatment may be followed by recurrent liver injury, readmission, and progression to cirrhosis.

 

Early Liver Transplantation Expands the High-Value Treatment Segment

Liver transplantation is the most resource-intensive option for selected patients who fail medical therapy. Historical practice often required six months of sobriety before listing, but many transplant programs are shifting toward individualized medical and psychosocial assessment because severe nonresponders may not survive that waiting period.

A multicenter U.S. cohort reported survival of 94% at one year and 84% at three years after early transplantation for severe alcoholic hepatitis. Following discharge, 72% remained abstinent, 18% experienced limited alcohol use, and 11% developed sustained alcohol use.

These outcomes support transplantation as an effective rescue treatment, but organ shortages, strict selection, limited center capacity, and lifelong immunosuppression prevent broad access. Transplantation therefore creates an important benchmark for pharmaceutical developers. A medicine that improves transplant-free survival could preserve scarce organs and avoid substantial lifetime costs.

 

Larsucosterol Leads the Late-Stage Pipeline

Larsucosterol is the most advanced pharmaceutical candidate in the alcoholic hepatitis market. The drug received FDA Fast Track and Breakthrough Therapy designations and was acquired by Bausch Health through its purchase of DURECT in September 2025.

The transaction included approximately USD 63 million in upfront cash and potential net-sales milestone payments of up to USD 350 million. This structure shows meaningful commercial interest while placing much of the value on future regulatory approval and market performance.

The Phase 2b AHFIRM trial enrolled 307 patients but did not meet its primary endpoint of significantly reducing death or liver transplantation at 90 days. Ninety-day mortality occurred in 25 of 103 placebo recipients, compared with 15 of 102 patients receiving 30 mg and 17 of 102 receiving 90 mg. The numerical reductions supported continued development but did not provide definitive evidence of efficacy.

A Phase 3 study began recruiting in 2026 and is expected to enroll approximately 350 adults with severe alcoholic hepatitis. The trial will evaluate transplant-free survival through day 90 in patients with Maddrey scores of at least 32 and MELD scores between 21 and 30.

Positive results could support the first approved disease-specific therapy and justify premium inpatient pricing. Failure would reinforce the difficulty of converting early mortality trends into a reproducible registration outcome.

 

Pipeline Attrition Highlights Development Risk

The pipeline includes therapies targeting inflammation, immune pathways, liver-cell repair, and regeneration. Development remains commercially uncertain because severe patients are medically unstable, supportive care varies between hospitals, and mortality endpoints require carefully designed trials.

Intercept Pharmaceuticals terminated its Phase 2 FRESH study of INT-787 on March 31, 2026, after finding no clear evidence of benefit in severe alcoholic hepatitis. The registry stated that the decision was not based on safety concerns

The termination reduces near-term competition for larsucosterol but also shows that promising liver-targeted mechanisms may not translate into improved survival. Future programs will require well-defined patient groups, sufficiently powered trials, consistent treatment standards, and endpoints that account for both death and transplantation.

 

North America Provides the Strongest Near-Term Commercial Opportunity

North America combines measurable hospital burden, high treatment costs, transplant infrastructure, active clinical research, and pharmaceutical investment.

An Ontario study of 3,340 adolescents and adults aged 13 to 39 found that alcoholic hepatitis rates increased by 8% annually. Rates rose by 11% per year among females and 7% among males. Among patients alive without cirrhosis six months after presentation, 22% later developed cirrhosis or decompensation.

The study also found that 74% required hospitalization, with a median stay of four days. Fifty-seven percent had previous mental-health encounters, 34% had encounters related to other substance use, and 71% had prior emergency or inpatient alcohol-related care. These findings support integrated hepatology, mental-health, and addiction treatment rather than a medicine-only model.

Europe also represents a significant market because of its alcohol-related liver-disease burden. The World Health Organization estimates that alcohol causes approximately 800,000 deaths annually across the WHO European Region, while the European Association for the Study of the Liver reports that alcohol accounts for almost half of liver-disease deaths in Europe.

Commercial demand across Europe will vary according to national alcohol-consumption patterns, hospital reimbursement, transplant policies, specialist capacity, and access to clinical trials.

 

Survival and Hospital Outcomes Will Determine Competitive Success

The alcoholic hepatitis treatment market currently lacks a strong branded pharmaceutical segment but contains a concentrated premium opportunity among severe hospitalized patients who are steroid-ineligible, nonresponsive, or at high risk of death or transplantation.

Future therapies must demonstrate more than reduced inflammation. Competitive differentiation will depend on credible improvement in 90-day transplant-free survival, manageable infection risk, compatibility with supportive care, and measurable effects on hospital resource use.

Payers will assess whether higher drug costs are offset by fewer intensive-care days, shorter admissions, reduced organ failure, lower readmission, or fewer transplants. With average 30-day inpatient costs reaching approximately USD 88,655, an effective medicine has a substantial economic pool from which to create value.

The market is gradually shifting from inexpensive supportive medicines toward survival-based pharmaceutical development. Larsucosterol’s Phase 3 program is the most important near-term catalyst, while the termination of INT-787 confirms the field’s high development risk. Until an investigational therapy produces a reproducible mortality benefit, corticosteroids, nutritional support, abstinence programs, complication management, and selected early transplantation will continue to account for most treatment activity and healthcare spending.

 

Alcoholic Hepatitis Treatment Market Report Coverage Table

Report Attribute	Details
Forecast Period	2026 – 2032
Market Size Value in 2025	USD 2.85 Billion
Revenue Forecast in 2032	USD 4.07 Billion
Overall Growth Rate	CAGR of 5.23% (2026 – 2032)
Base Year for Estimation	2025
Historical Data	2019 – 2024
Unit	USD Million, CAGR (2026 – 2032)
Segmentation	By Treatment Type, By Drug Class, By Disease Severity, By Route of Administration, By End User, By Geography
By Treatment Type	Supportive Care & Nutritional Therapy, Corticosteroid Therapy, Adjunctive Pharmacological Therapy, Alcohol Use Disorder Treatment, Liver Transplantation, Emerging Therapies
By Drug Class	Corticosteroids, N-Acetylcysteine, Alcohol Use Disorder Drugs, Investigational Disease-Modifying Drugs, Other Supportive Medicines
By Disease Severity	Mild Alcoholic Hepatitis, Moderate Alcoholic Hepatitis, Severe Alcoholic Hepatitis
By Route of Administration	Oral, Intravenous/Parenteral
By End User	Hospitals, Transplant Centers, Hepatology Clinics, Outpatient Addiction Care Centers, Research Institutes & Clinical Trial Sponsors
By Region	North America, Europe, Asia-Pacific, Latin America, Middle East and Africa
Country Scope	U.S., Canada, UK, Germany, France, Italy, Spain, China, Japan, South Korea, India, Brazil, Mexico, Saudi Arabia, UAE, South Africa
Market Drivers	Rising alcohol-associated liver disease burden, increasing hospitalization rates for severe alcoholic hepatitis, unmet need for disease-specific therapies, steroid nonresponse challenges, growth in hepatology clinical research, early liver transplantation adoption, and development of Phase 3 investigational treatments
Customization Option	Available upon request